TD Cowen analyst Tyler Van Buren has maintained their neutral stance on KROS stock, giving a Hold rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tyler Van Buren’s rating is based on Keros Therapeutics’ strategic decision to focus exclusively on the development of KER-065, which shows promising results in early trials for improving body composition and bone density. The company plans to advance KER-065 into a Phase II trial for DMD by early 2026, pending regulatory discussions, which indicates a clear research direction but also involves inherent risks and uncertainties typical of clinical trial progressions.
Additionally, the decision to discontinue cibotercept due to insufficient data and safety concerns reflects a prudent approach to resource allocation. Despite these strategic moves, Keros maintains a strong cash position, with enough funds to support operations into the first half of 2028, even after planning a significant capital return to shareholders. These factors collectively contribute to the Hold rating, balancing potential growth prospects with existing uncertainties.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KROS in relation to earlier this year.